Cyclerion Therapeutics Stock Forward View
| CYCN Stock | USD 1.10 0.02 1.85% |
Cyclerion Stock outlook is based on your current time horizon. Although Cyclerion Therapeutics' naive historical forecasting may sometimes provide an important future outlook for the firm, we suggest always cross-verifying it against solid analysis of Cyclerion Therapeutics' systematic risk associated with finding meaningful patterns of Cyclerion Therapeutics fundamentals over time.
As of today the rsi of Cyclerion Therapeutics' share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
Wall Street Target Price 8 | Quarterly Revenue Growth 3.51 |
Using Cyclerion Therapeutics hype-based prediction, you can estimate the value of Cyclerion Therapeutics from the perspective of Cyclerion Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The Naive Prediction forecasted value of Cyclerion Therapeutics on the next trading day is expected to be 0.88 with a mean absolute deviation of 0.1 and the sum of the absolute errors of 6.08. Cyclerion Therapeutics after-hype prediction price | USD 1.11 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Cyclerion | Build AI portfolio with Cyclerion Stock |
Cyclerion Therapeutics Additional Predictive Modules
Most predictive techniques to examine Cyclerion price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cyclerion using various technical indicators. When you analyze Cyclerion charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Cyclerion Therapeutics Cash Forecast
Forecasting financial indicators like cash flow involves analysts applying various statistical methods, techniques, and algorithms. These tools reveal hidden trends within the Cyclerion Therapeutics' financial statements to estimate their effects on upcoming price movements.
Cash | First Reported 2018-03-31 | Previous Quarter 3 M | Current Value 4.6 M | Quarterly Volatility 38.1 M |
Cyclerion Therapeutics Naive Prediction Price Forecast For the 10th of February
Given 90 days horizon, the Naive Prediction forecasted value of Cyclerion Therapeutics on the next trading day is expected to be 0.88 with a mean absolute deviation of 0.1, mean absolute percentage error of 0.02, and the sum of the absolute errors of 6.08.Please note that although there have been many attempts to predict Cyclerion Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cyclerion Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Cyclerion Therapeutics Stock Forecast Pattern
| Backtest Cyclerion Therapeutics | Cyclerion Therapeutics Price Prediction | Research Analysis |
Cyclerion Therapeutics Forecasted Value
In the context of forecasting Cyclerion Therapeutics' Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Cyclerion Therapeutics' downside and upside margins for the forecasting period are 0.01 and 8.55, respectively. We have considered Cyclerion Therapeutics' daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Naive Prediction forecasting method's relative quality and the estimations of the prediction error of Cyclerion Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Cyclerion Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 114.1871 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.0996 |
| MAPE | Mean absolute percentage error | 0.0669 |
| SAE | Sum of the absolute errors | 6.0753 |
Predictive Modules for Cyclerion Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cyclerion Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cyclerion Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cyclerion Therapeutics After-Hype Price Density Analysis
As far as predicting the price of Cyclerion Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cyclerion Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cyclerion Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cyclerion Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Cyclerion Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cyclerion Therapeutics' historical news coverage. Cyclerion Therapeutics' after-hype downside and upside margins for the prediction period are 0.06 and 8.78, respectively. We have considered Cyclerion Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cyclerion Therapeutics is dangerous at this time. Analysis and calculation of next after-hype price of Cyclerion Therapeutics is based on 3 months time horizon.
Cyclerion Therapeutics Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cyclerion Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cyclerion Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cyclerion Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.36 | 7.67 | 0.01 | 0.14 | 5 Events / Month | 6 Events / Month | In about 5 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
1.10 | 1.11 | 0.91 |
|
Cyclerion Therapeutics Hype Timeline
Cyclerion Therapeutics is currently traded for 1.10. The entity has historical hype elasticity of 0.01, and average elasticity to hype of competition of 0.14. Cyclerion is forecasted to increase in value after the next headline, with the price projected to jump to 1.11 or above. The average volatility of media hype impact on the company the price is over 100%. The price boost on the next news is projected to be 0.91%, whereas the daily expected return is currently at -0.36%. The volatility of related hype on Cyclerion Therapeutics is about 1976.8%, with the expected price after the next announcement by competition of 1.24. The company reported the previous year's revenue of 2 M. Net Loss for the year was (3.06 M) with profit before overhead, payroll, taxes, and interest of 2.65 M. Given the investment horizon of 90 days the next forecasted press release will be in about 5 days. Check out Historical Fundamental Analysis of Cyclerion Therapeutics to cross-verify your projections.Cyclerion Therapeutics Related Hype Analysis
Having access to credible news sources related to Cyclerion Therapeutics' direct competition is more important than ever and may enhance your ability to predict Cyclerion Therapeutics' future price movements. Getting to know how Cyclerion Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cyclerion Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| TCRT | Alaunos Therapeutics | 0.09 | 7 per month | 5.60 | 0.01 | 10.07 | (10.55) | 24.31 | |
| XTLB | XTL Biopharmaceuticals Ltd | (0.03) | 10 per month | 5.45 | 0.03 | 8.25 | (10.38) | 69.50 | |
| PLRZ | Polyrizon Ltd Ordinary | 4.52 | 9 per month | 7.09 | 0.12 | 31.36 | (15.16) | 149.99 | |
| QNRX | Quoin Pharmaceuticals Ltd | (0.92) | 12 per month | 0.00 | (0.01) | 18.69 | (11.19) | 77.47 | |
| KTTA | Pasithea Therapeutics Corp | 0.01 | 9 per month | 7.85 | 0.05 | 13.95 | (12.50) | 137.41 | |
| RADX | Radiopharm Theranostics Limited | 0.00 | 0 per month | 7.52 | 0.06 | 7.44 | (7.58) | 193.18 | |
| VYNE | Vyne Therapeutics | (0.12) | 7 per month | 2.34 | 0.12 | 5.71 | (5.26) | 55.08 | |
| NBY | NovaBay Pharmaceuticals | 0.01 | 18 per month | 15.59 | 0.07 | 33.70 | (29.80) | 158.53 | |
| ADXN | Addex Therapeutics | 0.44 | 7 per month | 0.00 | (0.04) | 7.85 | (7.12) | 25.13 | |
| AIM | AIM ImmunoTech | (0.12) | 8 per month | 0.00 | (0.12) | 10.14 | (10.32) | 29.72 |
Other Forecasting Options for Cyclerion Therapeutics
For every potential investor in Cyclerion, whether a beginner or expert, Cyclerion Therapeutics' price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Cyclerion Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Cyclerion. Basic forecasting techniques help filter out the noise by identifying Cyclerion Therapeutics' price trends.Cyclerion Therapeutics Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cyclerion Therapeutics stock to make a market-neutral strategy. Peer analysis of Cyclerion Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclerion Therapeutics by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Cyclerion Therapeutics Market Strength Events
Market strength indicators help investors to evaluate how Cyclerion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cyclerion Therapeutics shares will generate the highest return on investment. By undertsting and applying Cyclerion Therapeutics stock market strength indicators, traders can identify Cyclerion Therapeutics entry and exit signals to maximize returns.
Cyclerion Therapeutics Risk Indicators
The analysis of Cyclerion Therapeutics' basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Cyclerion Therapeutics' investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cyclerion stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.82 | |||
| Standard Deviation | 7.73 | |||
| Variance | 59.71 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cyclerion Therapeutics
The number of cover stories for Cyclerion Therapeutics depends on current market conditions and Cyclerion Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cyclerion Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cyclerion Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cyclerion Therapeutics Short Properties
Cyclerion Therapeutics' future price predictability will typically decrease when Cyclerion Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cyclerion Therapeutics often depends not only on the future outlook of the potential Cyclerion Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cyclerion Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.5 M | |
| Cash And Short Term Investments | 3.2 M |
Check out Historical Fundamental Analysis of Cyclerion Therapeutics to cross-verify your projections. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Will Biotechnology sector continue expanding? Could Cyclerion diversify its offerings? Factors like these will boost the valuation of Cyclerion Therapeutics. Projected growth potential of Cyclerion fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cyclerion Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.70) | Revenue Per Share | Quarterly Revenue Growth 3.51 | Return On Assets | Return On Equity |
Understanding Cyclerion Therapeutics requires distinguishing between market price and book value, where the latter reflects Cyclerion's accounting equity. The concept of intrinsic value - what Cyclerion Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Cyclerion Therapeutics' price substantially above or below its fundamental value.
It's important to distinguish between Cyclerion Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cyclerion Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cyclerion Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.